ライフサイエンスコーパス: antitumour

1 have similar structures, but differ in their antitumour activities and ecophysiological roles.

2 using NCPs as nanotherapeutics with enhanced antitumour activities, this study establishes NCPs as a

3 d fumaric acids) that showed antioxidant and antitumour activities, without hepatotoxicity.

4 ed pharmacokinetic profiling and preliminary antitumour activity (best response by Response Evaluatio

5 The decoction exhibited no antitumour activity (GI(50)>400 mug/mL) which could indi

6 nts a new therapy with clinically meaningful antitumour activity and a manageable safety profile in p

7 represent a new targeted therapy with robust antitumour activity and a manageable safety profile in p

8 INTERPRETATION: First-line pembrolizumab has antitumour activity and acceptable tolerability in cispl

9 metastatic Merkel cell carcinoma, has shown antitumour activity and an acceptable safety profile in

10 The combination has promising antitumour activity and further clinical development is

11 a pan-PI3K inhibitor, has shown preclinical antitumour activity and objective responses in patients

12 interleukin 1alpha, has been associated with antitumour activity and relief of debilitating symptoms

13 nal anti-PD-L1 antibody, has shown promising antitumour activity and safety in this disease.

14 We aimed to assess the antitumour activity and safety of dabrafenib plus tramet

15 ndrogen-receptor signalling, we assessed the antitumour activity and safety of MDV3100 in men with th

16 Data from phase 2 trials suggest that it has antitumour activity as a single agent in recurrent gliob

17 Regorafenib has antitumour activity as first-line treatment for metastat

18 amma 1I is an enediyne antibiotic possessing antitumour activity associated with its ability to bind

19 D-1) antibody pembrolizumab has shown potent antitumour activity at different doses and schedules in

20 Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-like growth

21 2) n NH2](NO3) 2[1,1/c,c ( n = 4,6)] exhibit antitumour activity comparable with cisplatin.

22 targeted nano-assembly exhibits significant antitumour activity in a mouse tumour model.

23 ble derivative of calcein, shows significant antitumour activity in a wide spectrum of cultured cance

24 suggest that a targeted inhibitor of ALK has antitumour activity in childhood malignancies harbouring

25 is a novel tubulin-binding taxane drug with antitumour activity in docetaxel-resistant cancers.

26 nisms of inhibition are required for optimal antitumour activity in each genotype.

27 Figitumumab is well tolerated and has antitumour activity in Ewing's sarcoma, warranting furth

28 receptor alpha monoclonal antibody that has antitumour activity in human sarcoma xenografts.

29 mentary mechanisms of action and synergistic antitumour activity in models of HER2-overexpressing bre

30 ase inhibitor (TKI) crizotinib showed marked antitumour activity in patients with advanced, ALK-posit

31 Alectinib was well tolerated, with promising antitumour activity in patients with ALK-rearranged NSCL

32 BRAF inhibition has shown antitumour activity in patients with BRAF(V600E)-mutant

33 rapamycin (mTOR) inhibitor with single-agent antitumour activity in patients with mantle cell lymphom

34 ose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive,

35 bined with trametinib, has shown substantial antitumour activity in patients with previously treated

36 umab showed an acceptable safety profile and antitumour activity in patients with progressive or trea

37 Vemurafenib showed antitumour activity in patients with progressive, BRAF(V

38 ession or ETS rearrangements and measures of antitumour activity in patients with prostate cancer.

39 e signal transduction provide well-tolerated antitumour activity in patients.

40 rated and demonstrated clinically meaningful antitumour activity in recurrent or metastatic squamous

41 factor receptor 1-3 inhibitor that has shown antitumour activity in recurrent ovarian cancer.

42 INTERPRETATION: Avelumab showed antitumour activity in the treatment of patients with pl

43 ll immune responses and exhibits significant antitumour activity in vivo.

44 Both oral agents have antitumour activity in women with recurrent ovarian canc

45 owed a manageable tolerability profile, with antitumour activity irrespective of PD-L1 status, and wa

46 se molecular mechanisms by which FBW7 exerts antitumour activity is an area of intensive investigatio

47 The potent in vivo antitumour activity is probably a result of the migratio

48 Antitumour activity observed for 43 natural and 10 comme

49 Despite compelling antitumour activity of antibodies targeting the programm

50 ase inhibitor, has been shown to enhance the antitumour activity of chemotherapy and radiotherapy in

51 inistration of an ERK inhibitor enhances the antitumour activity of CHK2 inhibition in both a human D

52 ne the safety, recommended phase 2 dose, and antitumour activity of crizotinib in children with refra

53 ding Ewing's sarcoma, and early reports show antitumour activity of IGF-1R-targeting drugs in these d

54 We aimed to assess the safety and antitumour activity of navitoclax in patients with lymph

55 nd pharmacodynamic profiles, and preliminary antitumour activity of niraparib.

56 derstanding the mechanisms that underlie the antitumour activity of non-steroidal anti-inflammatory d

57 imed to assess the safety, tolerability, and antitumour activity of pembrolizumab, a humanised anti-p

58 assess the safety, side-effect profile, and antitumour activity of pembrolizumab.

59 We assessed the antitumour activity of sonidegib, a Hedgehog signalling

60 However, as experience grows with the antitumour activity of these drugs, new toxic effects ar

61 n-naive) treated with avelumab and to assess antitumour activity of this drug in post-platinum patien

62 antibody tremelimumab might provide greater antitumour activity than either drug alone.

63 have a higher therapeutic index and greater antitumour activity than mitogen-activated protein kinas

64 Preliminary antitumour activity warrants further evaluation.

65 Antitumour activity was also recorded in brain metastase

66 Antitumour activity was also reported in sporadic high-g

67 Antitumour activity was assessed in post-platinum patien

68 In vivo antitumour activity was assessed in Sarcoma 180-bearing

69 eded 50% at doses greater than 80 mg/day and antitumour activity was documented beyond doses of 60 mg

70 -mutant non-melanoma solid tumours, apparent antitumour activity was noted in a gastrointestinal stro

71 Safety and antitumour activity were evaluated at data cutoff on Jun

72 egion showed 87.50+/-5.50% and 79.00+/-5.56% antitumour activity which were reference standard.

73 umab tesirine shows encouraging single-agent antitumour activity with a manageable safety profile.

74 umab tesirine shows encouraging single-agent antitumour activity with a manageable safety profile.

75 therapy and nivolumab plus ipilimumab showed antitumour activity with durable responses and manageabl

76 Previous phase 2 studies have shown antitumour activity with gemcitabine and oxaliplatin (GE

77 We recorded encouraging antitumour activity with MDV3100 in patients with castra

78 GEMOX-B showed antitumour activity with tolerable safety in patients wi

79 In a preliminary assessment of antitumour activity, 21 (55% [95% CI 38-71]) of 38 patie

80 ts that dasatinib kinase inhibition leads to antitumour activity, affects osteoclasts, and has synerg

81 e modulation of TH9 cell differentiation and antitumour activity, and prompt potential autophagy-depe

82 numerous physiological properties including antitumour activity, especially in colon cancer.

83 dy population, trastuzumab deruxtecan showed antitumour activity, even in low HER2-expressing tumours

84 taxel plus prednisone has important clinical antitumour activity, improving overall survival in patie

85 Despite this robust antitumour activity, most responses to these drugs are p

86 a manageable toxicity profile and promising antitumour activity, warranting further study in phase 2

87 ompounds with high antioxidant potential and antitumour activity.

88 ted here, and is associated with substantial antitumour activity.

89 ynamic effects on platelets and T cells, and antitumour activity.

90 in vitro data, clinical trials showed little antitumour activity.

91 ulature seems to be central to this distinct antitumour activity.

92 bution lymphocytosis, leading to more potent antitumour activity.

93 CD4(+) immunogenic mutations confers strong antitumour activity.

94 dpoints included pharmacodynamic effects and antitumour activity.

95 NA topoisomerase is the major target for the antitumour agent m-AMSA (4'-(9-acridinylamino)methanesul

96 ational repair can reduce sensitivity to the antitumour agent, presumably by eliminating the complex

97 he further development of HDAC inhibitors as antitumour agents.

98 t effects on the immune system - stimulating antitumour and antimicrobial activity, for example - by

99 ituent responsible for the antiinflammatory, antitumour and antioxidant activities of ginger.

100 The potential antitumour and disease-modifying role of adjuvant bispho

101 erial, antifungal, antiviral, antiparasitic, antitumour, anti-inflammatory, antioxidant, and immunomo

102 cin A is a member of a subfamily of enediyne antitumour antibiotics characterized by a 10-membered ca

103 controls the biosynthesis of the polyketide antitumour antibiotics daunorubicin and doxorubicin.

104 en pretargeted with a relevant FITC-labelled antitumour antibody.

105 several areas of bio-applications, including antitumour, antimicrobial, antioxidant and bioengineerin

106 Oxetanocin A (OXT-A) is a potent antitumour, antiviral and antibacterial compound.

107 ad range of bioactive metabolites, including antitumour aromatic compounds such as mithramycin and ma

108 one of a number of cytokines that can induce antitumour CD8(+) T cell responses.

109 uced by the clinically used nitrogen mustard antitumour drug mechlorethamine (HN2), were quantitated

110 and to develop these as a new generation of antitumour drugs.

111 cyte (CTL) response, can result in promising antitumour effect against several human malignancies, es

112 In the clinical setting the antitumour effect is less clear, but recent data suggest

113 has been implicated as a key effector of the antitumour effect of aspirin, but the effects of non-asp

114 The impaired antitumour effect of CD4(+) T cells with their defective

115 s which optimise an immunologically-mediated antitumour effect.

116 o treat melanoma in mice and observed a good antitumour effect.

117 Significant antitumour effects are observed in piperlongumine-treate

118 We noted antitumour effects at all doses, including decreases in

119 TNFalpha gene delivery has produced striking antitumour effects in model systems in animals.

120 Preclinical studies have reported direct antitumour effects of bisphosphonates, particularly in c

121 ompetitive RAF kinase inhibitors have potent antitumour effects on mutant BRAF(V600E) tumours but, in

122 rticularly radiotherapy, may exert important antitumour effects through actions on the vasculature as

123 erting specifically tailored transgenes with antitumour effects to create tumour-seeking therapeutic

124 ABP4 by siRNA in vivo has antiangiogenic and antitumour effects with minimal toxicity and should be i

125 ions at SMO have been found to abolish their antitumour effects, a phenomenon known as chemoresistanc

126 HIV protease; however, they have pleiotropic antitumour effects, including inhibition of inflammatory

127 suggest that platelets may be central to the antitumour efficacy of aspirin.

128 ion after cisplatin without compromising the antitumour efficacy of cisplatin.

129 We aimed to ascertain the antitumour efficacy of ipilimumab in patients with advan

130 of immunogenic nanoparticles to augment the antitumour efficacy of PD-L1 antibody-mediated cancer im

131 Further studies are needed to confirm the antitumour efficacy of the combination of a somatostatin

132 ticles act similarly to Metformin and induce antitumour efficacy through activation of the AMPK and i

133 -related cardiotoxicity without compromising antitumour efficacy.

134 mpatibility; as a result, we achieved better antitumour efficacy.

135 ovide evidence to support the presence of an antitumour immune response in advanced thyroid cancers l

136 t different RT responses primarily due to an antitumour immune response.

137 microenvironment as an important part of the antitumour immune response.

138 2-targeted phagocytosis and produced durable antitumour immune responses against HER2-expressing tumo

139 Endogenous or iatrogenic antitumour immune responses can improve the course of fo

140 her they are sufficient to induce protective antitumour immune responses or whether their expression

141 nce, immunity and immunosuppression regulate antitumour immune responses together with the advent of

142 th DC stimuli induced potent T-cell-mediated antitumour immune responses, resulting in tumour eradica

143 cal studies have found radiotherapy enhances antitumour immune responses.

144 bodies and associated effector cells in both antitumour immune surveillance and therapy.

145 and simultaneously generates potent systemic antitumour immunity against poorly immunogenic B16F10 in

146 mBiNE was receptor dependent, the subsequent antitumour immunity also generated protective effects ag

147 d DCs as a powerful inducer of Th9 cells and antitumour immunity and may have important clinical impl

148 ributes to the induction of antigen-specific antitumour immunity and pathogenesis of graft-versus-hos

149 d to investigate the prognostic role of host antitumour immunity as represented by baseline quantitie

150 rall survival, suggesting that the effect of antitumour immunity extends to the advanced setting.

151 rall survival, suggesting that the effect of antitumour immunity extends to the advanced setting.

152 ibited clear treatment efficacy and systemic antitumour immunity in ovarian, colon, and breast tumour

153 r-binding allogeneic IgG can induce powerful antitumour immunity that can be exploited for cancer imm

154 nges may be an effective strategy to enhance antitumour immunity that prevents tumour progression, as

155 ression and subsequently stimulates systemic antitumour immunity to treat metastases.

156 CD8(+) T cells have a central role in antitumour immunity, but their activity is suppressed in

157 d the mechanisms by which tumour cells evade antitumour immunity, the field of cancer immunotherapy h

158 Mechanistically, LCMV induces antitumour immunity, which depends on the recruitment of

159 cytotoxic T-lymphocyte antigen 4 to enhance antitumour immunity.

160 -associated inflammation actively suppresses antitumour immunity.

161 at promotes immune resistance and attenuates antitumour immunity.

162 1 to negatively modulate TH9 homeostasis and antitumour immunity.

163 ion in the tumour microenvironment restricts antitumour immunity.

164 vascular sites has emerged as a key step in antitumour immunity.

165 istetraprolin, contributing to regulation of antitumour immunity.IL-27 is one of a number of cytokine

166 The results show an antitumour interaction between ionizing radiation and an

167 owth, suggesting the generation of long-term antitumour memory.

168 There is evidence that antitumour necrosis factor alpha (TNFalpha) is efficacio

169 The recently developed antitumour necrosis factor drugs may also reduce coronar

170 Treatment advances include antitumour necrosis factor- alpha drugs; however, these

171 Biologic therapies, including the antitumour necrosis factor-alpha agents and interferons,

172 and case reports using mainly rituximab and antitumour necrosis factor-alpha agents to treat these d

173 fficacy, the main exception being the use of antitumour necrosis factor-alpha agents with cyclophosph

174 e-modifying antirheumatic drugs (DMARDs) and antitumour necrosis factor-alpha biologic agents.

175 MTX and antitumour necrosis factor-alpha drugs also appear to ha

176 enotypic cell state transition for improving antitumour outcome could emerge as a translational strat

177 power and lipid peroxidation inhibition) and antitumour potential (against breast, lung, cervical and

178 dy focuses on exploration of antioxidant and antitumour potential as well as total phenolic contents

179 Antitumour potential of honey is attributed to its excel

180 i honeys possessed excellent antioxidant and antitumour potential overall.

181 ochemicals with bioactive properties (mainly antitumour potential selective to colon and cervical car

182 er and inhibition of lipid peroxidation; the antitumour potential was tested in human tumour cell lin

183 er and inhibition of lipid peroxidation, the antitumour potential was tested in human tumour cell lin

184 a lower antioxidant potential and absence of antitumour potential.

185 ified DNA has been postulated to mediate the antitumour properties of the drug.

186 The potential antitumour properties of these drugs have been investiga

187 rosis factor alpha (TNFalpha), named for its antitumour properties, was isolated almost 30 years ago.

188 anocarrier leads to a significantly improved antitumour response in both breast cancer and melanoma m

189 Here we report a new mechanism by which the antitumour response of mouse CD8(+) T cells can be poten

190 e with dectin-1-activated DCs induces potent antitumour response that depends on Th9 cells and IL-9 i

191 This antitumour response, however, is likely blunted by the p

192 acute and chronic xerostomia with preserved antitumour response, some institutions are now adding am

193 s and is thereby a negative regulator of the antitumour response.

194 ion than they are to mount an effective host antitumour response.

195 nd adaptive immunity and promote a universal antitumour response.

196 on of cytotoxic T cells, leading to improved antitumour responses in vivo, and elicited proportionall

197 itical for priming effective and therapeutic antitumour responses.

198 The heterogeneity among the antioxidant and antitumour results of the samples and some low correlati

199 pathways exploited by tumours is a promising antitumour strategy, especially when combined with other

200 In the in vivo antitumour study, tumour growth inhibition rates were 31

201 PD-L1 and CTLA-4 immune checkpoints inhibit antitumour T-cell activity.

202 ng by gefitinib destabilizes PD-L1, enhances antitumour T-cell immunity and therapeutic efficacy of P

203 wever, whether dectin-1 directs DCs to prime antitumour Th9 cells remains unclear.

204 gated as promising targets for the design of antitumour therapies.

205 hich may act as a critical block to existing antitumour therapies.

206 basic cancer biology and the development of antitumour therapy.

207 afts, enabling an effective single-treatment antitumour therapy.

208 hat HM-3A is worth further investigation for antitumour use.

209 n calreticulin exposure on the cell surface, antitumour vaccination and an abscopal effect.